News
BLRX
2.380
+3.03%
0.070
Weekly Report: what happened at BLRX last week (0406-0410)?
Weekly Report · 1d ago
BioLineRx files Form 3 as director Shaoyu Yan reports no beneficial ownership
Reuters · 4d ago
BioLineRx, Hemispherian initiate clinical trial of GLIX1
TipRanks · 6d ago
BioLineRx partner Hemispherian starts Phase 1/2a GLIX1 trial in glioblastoma
Reuters · 6d ago
Weekly Report: what happened at BLRX last week (0330-0403)?
Weekly Report · 04/06 09:54
BioLineRx files Form 3 as Director Sandra Panem reports beneficial ownership
Reuters · 03/31 20:20
BioLineRx files Form 3 for Director Raphael Hofstein initial beneficial ownership statement
Reuters · 03/31 20:12
BioLineRx files Form 3 disclosing director Rami Dar beneficial ownership
Reuters · 03/31 20:12
BioLineRx files initial beneficial ownership statement for director Avraham Molcho
Reuters · 03/31 20:02
BioLineRx director Gal Cohen files initial beneficial ownership statement
Reuters · 03/30 22:15
BioLineRx files Form 3 as director Aharon Schwartz reports stake
Reuters · 03/30 22:15
Weekly Report: what happened at BLRX last week (0323-0327)?
Weekly Report · 03/30 09:55
BioLineRx: Advancing GLIX1 and Motixafortide Pipeline with Strengthened IP and Legal Position Underpinning Buy Rating and $12 Target
TipRanks · 03/28 03:55
BioLineRx files initial beneficial ownership statement; CEO Philip A. Serlin reports 5.1 million ordinary shares owned directly
Reuters · 03/27 20:07
BioLineRx Launches First-in-Human Trial of GLIX1 for Glioblastoma
TipRanks · 03/26 11:28
BioLineRx Launches First Human Trial For Brain Cancer Drug
Benzinga · 03/26 11:17
BioLineRx initiates Phase 1/2a GLIX1 trial in recurrent glioblastoma; data narrows to H1 2027
Reuters · 03/26 11:01
BIOLINERX ANNOUNCES INITIATION OF PHASE 1/2A STUDY OF GLIX1 FOR THE TREATMENT OF GLIOBLASTOMA (GBM)
Reuters · 03/26 11:00
BioLineRx Announces Initiation of Phase 1/2a Study of GLIX1 for the Treatment of Glioblastoma (GBM)
PR Newswire · 03/26 11:00
BioLine Rx Q4 EPADS $(0.34) Beats $(0.54) Estimate, Sales $194.000K Miss $651.598K Estimate
Benzinga · 03/24 13:06
More
Webull provides a variety of real-time BLRX stock news. You can receive the latest news about Biolinerx through multiple platforms. This information may help you make smarter investment decisions.
About BLRX
BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.